Ovid Therapeutics Announces First Patient Randomized in Clinical Trial

Pharmaceutical Investing

Ovid Therapeutics announced it has randomized the first patient in its Phase 1b/2a clinical trial of TAK-935, in collaboration with Takeda Pharmaceutical.

Ovid Therapeutics (NASDAQ:OVID) announced it has randomized the first patient in its Phase 1b/2a clinical trial of TAK-935, in collaboration with Takeda Pharmaceutical.
As quoted in the press release:

This marks the second program Ovid has advanced into Phase 2 clinical development this year.

Takeda and Ovid formed a global collaboration focused on the clinical development and commercialization of TAK-935/OV935, a potent and highly selective cholesterol 24-hydroxylase (CH24H) inhibitor, being investigated in adults with developmental and/or epileptic encephalopathies in January 2017.
“We are excited to achieve this important milestone as this is the first clinical trial in our collaboration with Ovid and TAK-935/OV935 is the first CH24H inhibitor in clinical development,” said Dr. Emiliangelo Ratti, head of Takeda’s Central Nervous System Therapeutic Area Unit. “While there are many treatments available for epilepsy, few therapeutic options exist for patients with developmental and/or epileptic encephalopathies, which cause intractable seizures that are often associated with cognitive, neurologic and behavioral symptoms. Our collaboration with Ovid is geared to leverage each company’s strengths to jointly develop this investigational medicine for people living with rare epilepsies.”

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×